BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

GlobeNewswire05-07

Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis GSK to participate in Series C Extension with equity investment Series C ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2433338211?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_Azeu3tRQOLUkzNjy_Avkg--~B/aD0zNDQ7dz0xNTk4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/1c3f5cc4e59ab90e535e1babc8b81e14","is_english":true,"pubTime":"2024-05-07 13:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2433338211","market":"us","top_or_hot":-1,"title":"BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million","media":"GlobeNewswire","content":"<div>\n<p>Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis\nGSK to participate in Series C Extension with equity investment\nSeries C ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bioversys-announces-expansion-strategic-collaboration-050000549.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-07 13:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bioversys-announces-expansion-strategic-collaboration-050000549.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis\nGSK to participate in Series C Extension with equity investment\nSeries C ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bioversys-announces-expansion-strategic-collaboration-050000549.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://finance.yahoo.com/news/bioversys-announces-expansion-strategic-collaboration-050000549.html","article_id":"2433338211","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_Azeu3tRQOLUkzNjy_Avkg--~B/aD0zNDQ7dz0xNTk4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/1c3f5cc4e59ab90e535e1babc8b81e14"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2433338211","pubTimestamp":1715058000,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis. GSK to participate in Series C Extension with equity investment. BASEL, Switzerland, May 07, 2024  -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant  bacteria, announced today the expansion of its strategic collaboration with the global biopharma company GSK plc  to accelerate the clinical development of alpibectir  for the treatment of tuberculosis .GSK and BioVersys will continue their collaboration beyond the current Phase 2a and develop alpibectir in both TB pulmonary and TB meningitis programs in order to make alpibectir available to patients as soon as possible.Thomas Breuer, Chief Global Health Officer, GSK: \"GSK is committed to changing the trajectory of tuberculosis and we’re excited to expand","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克","GSK":"葛兰素史克","BK4585":"ETF&股票定投概念"},"translate_title":"BioVersys宣布扩大与葛兰素史克的战略合作，并将其C轮融资延长1230万瑞士法郎","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1,"GSK.UK":0.6},"content_text":"Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis\nGSK to participate in Series C Extension with equity investment\nSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million\n\nBASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (\"MDR\") bacteria, announced today the expansion of its strategic collaboration with the global biopharma company GSK plc (LSE/NYSE: GSK) to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of tuberculosis (TB).\nAlpibectir, a small molecule acting through a novel mode of action, was developed in a successful public-private collaboration with GSK, Pasteur Institute Lille and the University of Lille and is currently being evaluated in combination with ethionamide (Eto) in a Phase 2a proof-of-concept study in pulmonary TB patients in South Africa. The compound represents a totally new concept of overcoming resistance and significantly potentiating the activity of an existing antibiotic, ethionamide (Eto).\nGSK and BioVersys will continue their collaboration beyond the current Phase 2a and develop alpibectir in both TB pulmonary and TB meningitis programs in order to make alpibectir available to patients as soon as possible.\nAs part of the expanded collaboration, GSK will take an equity stake in BioVersys' latest investment round. Adding to further investments from existing and new investors, this extends the Series C financing by CHF 12.3 million, resulting in total proceeds of CHF 44.9 million for the Series C round to date. The additional proceeds will enable the further clinical development of BioVersys’ portfolio which also includes BV100, a potential breakthrough hospital antibiotic with a new mode of action targeting Acinetobacter baumannii, the most drug-resistant bacterial pathogen.  \nDr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys: \"We are very pleased to announce both the expansion of our highly successful strategic collaboration with GSK and our partner’s participation in our latest financing round. Together with GSK, we successfully advanced the development of alpibectir for TB, having recently completed the TRIC-TB public-private partnership program with the delivery of a Phase 2-ready anti-TB molecule. We look forward to further expanding this collaboration with GSK beyond our ongoing Phase 2a evaluation of alpibectir, as we seek to deliver a new treatment regimen for TB, a disease that poses a serious threat to public health worldwide and which is severely underserved by current therapies.\"\nThomas Breuer, Chief Global Health Officer, GSK: \"GSK is committed to changing the trajectory of tuberculosis and we’re excited to expand our partnership with BioVersys in the continued development of alpibectir, a drug candidate with the potential to broaden the treatment options for TB. We believe that working in partnership on priorities that are aligned to and support global health challenges gives both companies the opportunity to achieve maximum health impact at scale.”\nAbout tuberculosis (TB) Tuberculosis (TB) is one of the leading causes of death worldwide. Its causative agent is the bacterial pathogen Mycobacterium tuberculosis (Mtb). Worldwide, an estimated 10.6 million people developed TB in 2022 and an estimated 1.30 million died from TB. WHO estimates that there were 410’000 new cases with resistance to rifampicin – the most effective first-line drug – most of them were multi-drug resistant (MDR). MDR-TB remains a public health crisis and a health security threat. Worldwide, only 63% of MDR-TB patients are currently successfully treated.1 In the modern world of global travel, and ease with which infections spread, it is very worrying to note that two-thirds of the global total of TB cases was in eight countries: India (27%), Indonesia (10%), China (7.1%), the Philippines (7.0%), Pakistan (5.7%), Nigeria (4.5%), Bangladesh (3.6%) and the Democratic Republic of the Congo (3.0%). Furthermore, 3.3% of all new and 17% of reoccurring TB cases were MDR/RR-TB.  \nAbout GSKGSK is a science-led global healthcare company. For further information please visit https://www.gsk.com/en-gb/about-us/\nAbout BioVersysBioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2), and tuberculosis (alpibectir, Phase 2a, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland.\nBioVersys contact Sylvia Mundt, Executive Assistant to CEO, Tel. +41 61 633 22 50; Mail: IR@bioversys.com Website: www.bioversys.comX: www.twitter.com/BioversysLinkedin: www.linkedin.com/company/bioversys-ag\n_________________________________________1 Global Tuberculosis Report 2023 WHO","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2433338211"}